PEGINTERFERON ALFA-2A

Summary

Peginterferon Alfa-2A (CHEMBL1201560) is an approved protein (ATC L03AB11); indicated across 29 conditions including chronic hepatitis b virus infection and chronic hepatitis c virus infection; with CIViC clinical evidence for 1 variant-indication association (e.g. CALR EXON 9 FRAMESHIFT in essential thrombocythemia).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AB11 (+1 more)
• Indications: 29 conditions
• Clinical trials: 248
• Precision-oncology evidence (CIViC): 1 variant–indication association

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201560
Name	PEGINTERFERON ALFA-2A
Type	Protein
Max phase	4
ATC	L03AB11, L03AB61

Also known as: Peg-interferon alfa 2a, Peg-interferon alfa-2a, Pegasys, Peginterferon .alpha.-2a, Peginterferon alfa, Peginterferon alfa-2a, Peginterferon-alfa-2a, Pegyinterferon-alfa-2a, Pegylated interferon alfa-2a, Pegylated interferon alpha 2a, Pegylated-interferon alfa 2a, Pegylated-interferon-alfa-2a

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
chronic hepatitis B virus infection	4	MONDO:0005366	EFO:0004239
chronic hepatitis C virus infection	4	MONDO:0005354	EFO:0004220
hepatitis B virus infection	4	MONDO:0005344	EFO:0004197
neoplasm	4	MONDO:0005070	EFO:0000616

21 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hepatitis C virus infection	3	MONDO:0005231	EFO:0003047
HIV infectious disease	3	MONDO:0005109	EFO:0000764
melanoma	3	MONDO:0005105	EFO:0000756
primary myelofibrosis	3	MONDO:0009692	EFO:0002430
chronic myeloid leukemia	3	MONDO:0011996	EFO:0000339
hepatitis D virus infection	3	MONDO:0005789	EFO:0007304
essential thrombocythemia	3	MONDO:0005029	EFO:0000479
acquired polycythemia vera	3	MONDO:0009891	EFO:0002429
cirrhosis of liver	3	MONDO:0005155	EFO:0001422
hepatitis	3	MONDO:0002251	HP:0012115
depressive disorder	3	MONDO:0002050	MONDO:0002050
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
thrombocytopenia	2	MONDO:0002049	HP:0001873
Clostridium infectious disease	2	MONDO:0024388	EFO:1000874
diffuse intrinsic pontine glioma	2	MONDO:0006033	EFO:1000026
breast neoplasm	2	MONDO:0021100	MONDO:0007254
colonic neoplasm	2	MONDO:0005401	MONDO:0021063
kidney disorder	2	MONDO:0005240	EFO:0003086
B-cell chronic lymphocytic leukemia	1	MONDO:0004948	EFO:0000095
kidney cancer	1	MONDO:0002367	MONDO:0002367

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 248.

Phase distribution

Phase	Trials
PHASE2	66
PHASE4	64
PHASE3	55
Not specified	32
PHASE1	13
PHASE2/PHASE3	9
PHASE1/PHASE2	9

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00028093	PHASE4	COMPLETED	Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease
NCT00056862	PHASE4	COMPLETED	Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
NCT00107653	PHASE4	COMPLETED	Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.
NCT00172809	PHASE4	COMPLETED	Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease
NCT00207311	PHASE4	COMPLETED	Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus
NCT00275548	PHASE4	COMPLETED	Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C
NCT00351403	PHASE4	COMPLETED	Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection
NCT00353418	PHASE4	COMPLETED	A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection
NCT00356486	PHASE4	COMPLETED	Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV
NCT00394277	PHASE4	COMPLETED	A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
NCT00436163	PHASE4	COMPLETED	A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B
NCT00491179	PHASE4	COMPLETED	Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin
NCT00491244	PHASE4	COMPLETED	Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
NCT00502099	PHASE4	COMPLETED	Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4
NCT00526448	PHASE4	UNKNOWN	Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients
NCT00540345	PHASE4	COMPLETED	Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C
NCT00553930	PHASE4	COMPLETED	Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients
NCT00560274	PHASE4	COMPLETED	A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
NCT00612755	PHASE4	COMPLETED	Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
NCT00629967	PHASE4	COMPLETED	A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients
NCT00630084	PHASE4	COMPLETED	Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
NCT00641654	PHASE4	TERMINATED	Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin
NCT00680173	PHASE4	COMPLETED	Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients
NCT00800748	PHASE4	COMPLETED	A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C
NCT00830609	PHASE4	COMPLETED	High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3
NCT00845676	PHASE4	COMPLETED	Treatment of Acute Hepatitis C Virus in HIV Co-Infection
NCT00917358	PHASE4	COMPLETED	Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C
NCT00921180	PHASE4	UNKNOWN	Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B
NCT00948220	PHASE4	COMPLETED	Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C
NCT01056172	PHASE4	UNKNOWN	PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)
NCT01336010	PHASE4	COMPLETED	Treatment of Recently Acquired Hepatitis C Virus Infection
NCT01373684	PHASE4	COMPLETED	PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients
NCT01378104	PHASE4	COMPLETED	100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)
NCT01415141	PHASE4	WITHDRAWN	Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism
NCT01447420	PHASE4	COMPLETED	A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
NCT01456312	PHASE4	UNKNOWN	HBsAg Related Response Guided Therapy
NCT01467492	PHASE4	TERMINATED	Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
NCT01592006	PHASE4	TERMINATED	Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients
NCT01684787	PHASE4	COMPLETED	Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients
NCT02068365	PHASE4	COMPLETED	An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy
NCT02097004	PHASE4	COMPLETED	Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection
NCT02377856	PHASE4	COMPLETED	Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection
NCT02474316	PHASE4	UNKNOWN	Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients
NCT02570191	PHASE4	COMPLETED	A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)
NCT02598063	PHASE4	COMPLETED	A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
NCT02601976	PHASE4	COMPLETED	Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population
NCT02604823	PHASE4	COMPLETED	A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)
NCT02641379	PHASE4	COMPLETED	A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)
NCT02745704	PHASE4	UNKNOWN	The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg
NCT02791269	PHASE4	COMPLETED	A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
NCT02822547	PHASE4	UNKNOWN	Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults
NCT02838810	PHASE4	UNKNOWN	The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg
NCT02864199	PHASE4	COMPLETED	A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment
NCT02893124	PHASE4	UNKNOWN	The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg
NCT02894918	PHASE4	UNKNOWN	A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
NCT02908763	PHASE4	UNKNOWN	HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients
NCT03013556	PHASE4	UNKNOWN	Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients
NCT03084250	PHASE4	UNKNOWN	The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
NCT03208998	PHASE4	UNKNOWN	The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy
NCT03209011	PHASE4	UNKNOWN	The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy
NCT03209037	PHASE4	UNKNOWN	The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy
NCT03253250	PHASE4	UNKNOWN	The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
NCT03801538	PHASE4	UNKNOWN	The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg
NCT06922643	PHASE4	COMPLETED	Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital
NCT00006164	PHASE3	COMPLETED	Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
NCT00038974	PHASE3	COMPLETED	Hepatitis C Antiviral Resistance in African-Americans
NCT00039962	PHASE3	COMPLETED	Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin
NCT00040027	PHASE3	COMPLETED	Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin
NCT00048945	PHASE3	COMPLETED	Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
NCT00093093	PHASE3	COMPLETED	Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive
NCT00136318	PHASE3	COMPLETED	Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients
NCT00144469	PHASE3	COMPLETED	A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C
NCT00221286	PHASE3	TERMINATED	Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients
NCT00221624	PHASE3	COMPLETED	Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients
NCT00299923	PHASE3	UNKNOWN	Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy
NCT00336518	PHASE3	UNKNOWN	Continuing Treatment With Pegasys and Copegus
NCT00381953	PHASE3	COMPLETED	High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
NCT00391638	PHASE2/PHASE3	COMPLETED	Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients
NCT00402428	PHASE3	COMPLETED	Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients
NCT00411385	PHASE3	COMPLETED	Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
NCT00421434	PHASE2/PHASE3	COMPLETED	Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C
NCT00527540	PHASE3	COMPLETED	Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C
NCT00623428	PHASE3	COMPLETED	A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response
NCT00758043	PHASE3	COMPLETED	A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
NCT00845065	PHASE3	COMPLETED	Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)
NCT01006031	PHASE2/PHASE3	COMPLETED	Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
NCT01241760	PHASE3	COMPLETED	VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection
NCT01259856	PHASE3	COMPLETED	Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
NCT01276756	PHASE2/PHASE3	COMPLETED	Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)
NCT01318694	PHASE3	COMPLETED	Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
NCT01387763	PHASE3	COMPLETED	A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
NCT01389323	PHASE3	COMPLETED	BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
NCT01446250	PHASE3	TERMINATED	Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
NCT01447394	PHASE3	WITHDRAWN	Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C
NCT01448044	PHASE3	COMPLETED	Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C
NCT01459913	PHASE3	TERMINATED	Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
NCT01467479	PHASE3	TERMINATED	A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
NCT01471574	PHASE3	COMPLETED	Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
NCT01492426	PHASE3	COMPLETED	Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
NCT01498068	PHASE3	COMPLETED	Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
CALR EXON 9 FRAMESHIFT	Essential Thrombocythemia	Sensitivity/Response	Peginterferon Alfa-2a	CIViC B	EID1482

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).